That was a good interview on BNN. 1. Clarified why the costs/gram were higher and rev lower. Plausible. I live in Calgary, and it was a miserable spring for weather.
2. Pushed the point that the Canadian rec market is not as critical as many would believe - its the international medicinal ,market that that will be most lucrative.
3. Emphasized that LEAF approached them, no the other way around. Some confidence that ACB will not overpay.
4. Empahsized they are gorwing faster than anyone else.
5. Clarified that Canimed revs (and costs) were not included in the results. That key, because, those should affect both price and cost positively.
I still have near term reservations that they will do a bad deal with LEAF, but long term not as many concerns.